PRF1 and neoplasm: Through flow cytometry analysis, we found that CD39i treatment promoted T-cell proliferation (Supplementary Fig. 9A, B) and enhanced T-cell tumor killing function by secreting more granzyme B and perforin, but not IFN-γ (Supplementary Fig. 9C-H).